Find us on:


Research Type
Reported as
Publication Type
Sort By
Total: 152
Low-dose naltrexone therapy in benign chronic pemphigus (Hailey-Hailey disease): a case series.
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 16, 2019 Authors C. Riquelme-Mc Loughlin, J. Riera-Monroig, D. Morgado-Carrasco, P. Giavedoni, S. Podlipnik, P. Iranzo, J.M. Mascaró Jr Institution University of Barcelona Disease Hailey-Hailey
University of Barcelona physicians studied the effect of low dose naltrexone (LDN) on 14 patients with Hailey-Hailey disease (HDD), also known as benign chronic pemphigus. The authors suggest that future studies be done to determine if certain genetic profiles are associated with favorable responses to LDN....
Use of low-dose naltrexone in the treatment of severe Hailey-Hailey disease: one case report.
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 08, 2019 Authors María Garayar Cantero, Marina Canseco Martín, Ángel Aguado García, Pilar Manchado López Institution Hospital Clínico Universitario de Valladolid Disease Hailey-Hailey
INTRODUCTION: Hailey-Hailey disease (HHD) or chronic benign familial pemphigus is an autosomal dominant genodermatosis with complete penetrance characterized by painful vesicles, erosions and macerated intertriginous skin. CASE REPORT: We present a 66-year-old woman with a personal 35-year history of pruritic recurrent vesicles and erosions in both axillae and inguinal folds. HHD was confirmed by cutaneous biopsy. Past treatments had failed, including topical corticosteroids, antibiotics and ...
Low Dose Naltrexone for Neuropathic Pain Related to an Electrical Burn Injury: A Case Study
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 01, 2019 Authors M. Cowling, M. Poliak-Tunis Institution University of Wisconsin Disease Chronic Pain
A 36- year old male with a past history significant for bipolar disorder, depression, and PTSD presented to UW Pain Clinic for management of ongoing pain related to an electrical burn injury (4.5%) to the left hand and flank sustained in August 2016. He underwent a skin graft for the burn six months later and has experienced difficulties with his pain since. During the consult, the patient described his pain as a burning, tingling sensation over the left flank and hand. He also experiences sharp...
Low-Dose Naltrexone in the Treatment of Fibromyalgia: A Retrospective Analysis
Research Type Human Reported as Case Report/Series/Restrospective Study Date April 01, 2019 Authors Jordan Wulz Institution Ascension Wisconsin Center for Pain Management, Concordia University Wisconsin Disease Fibromyalgia
The first scientific reference of fibromyalgia as a medical disorder occurred in 1981. Since then, pain management experts have continuously debated diagnosis criteria, potential pathologies, and viable treatment options due to the complex nature of the disease. For both patient and clinician, the efficacy of current pharmacologic treatments can be frustrating. The clinical benefit of medications is often modest at best. In fact, the 2016 European League Against Rheumatism (EULAR) guideline for ...
Inexpensive compounding of low dose naltrexone (LDN) with orange juice.
Research Type Human Reported as Opinion Date March 28, 2019 Authors R. Bronfenbrener Institution University of Pennsylvania, Yardley Dermatology Associates
One can compound LDN using commercially available tablets and orange juice. Doing so helps improve the texture and taste over using water. The ratio of medicine to juice is described. It is recommended to keep the mixture in the refrigerator and shake it prior to dispensing. Other juice flavors can be used based on patient preference. Following this procedure, patients can expect to get 3 months of medicine for about $15. Making LDN inexpensively should allow for the expansion of the use of LDN....
Systemic administration of low-dose naltrexone increases bone mass due to blockade of opioid growth factor receptor signaling in mice osteoblasts.
Research Type Lab (in-vitro) Reported as Clinical Trial Date March 28, 2019 Authors K. Tanaka, H. Kondo, K. Hamamura, A. Togari Institution Aichi-Gakuin University
AIMS: Opioid receptor blockers such as naloxone and naltrexone have been suggested to have a bone mass-increasing effect. However, the mechanisms at play have not been clarified. We examined the effects of naltrexone on osteoblasts and determined the expression of opioid growth factor receptor (OGFR) in osteoblasts. Naltrexone blocks the OGFR and other canonical opioid receptors. Thus, we designed experiments to clarify the effects of naltrexone on bone tissue by examining the physiological role...
Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes
Research Type Human Reported as Review Date March 27, 2019 Authors Diana Trofimovitch, Steven J. Baumrucker Institution East Tennessee State University College of Medicine, Ballad Health System Hospice and Palliative Medicine Disease Chronic Pain
Pain can have a devastating effect on the quality of life of patients in palliative medicine. Thus far, majority of research has been centered on opioid-based pain management, with a limited empirical evidence for the use of nonopioid medications in palliative care. However, opioid and nonopioid medications such as nonsteroidal anti-inflammatory drugs have their limitations in the clinical use due to risk of adverse effects, therefore, there is a need for more research to be directed to finding ...
The use of naltrexone in dermatology. Current evidence and future directions.
Research Type Human Reported as Review Date March 18, 2019 Authors Mariusz Sikora, Adriana Rakowska, Małgorzata Olszewska, Lidia Rudnicka Institution Medical University of Warsaw
Naltrexone is a competitive opioid receptor antagonist approved as supportive treatment in alcohol dependence and opioid addiction. In a dose 50-100 mg daily, naltrexone is used off-label in dermatology for the treatment of trichotillomania and different types of pruritus. At a dose as low as 1-5 mg of drug per day, naltrexone demonstrates immunomodulatory action i.e. modulates Toll-like receptors signaling, decreases release of proinflammatory cytokines (tumor necrosis factor, interleukin-6, in...
Disease remission after commencing naltrexone in an atypical case of Crohn’s disease complicated by recurrent Clostridium difficile infection
Research Type Human Reported as Case Report/Series/Restrospective Study Date March 18, 2019 Authors Afrasyab Khan, John Perry Institution Waitemata District Health Board North Shore Hospital, Counties Manukau Health Middlemore Hospital Disease Crohn's Disease
INTRODUCTION: Crohn’s disease (CD) is typically a chronic relapsing condition of the gastrointestinal tract. Granulomas can be present which are typically non-necrotizing. CD can be triggered as well as complicated by gastrointestinal infections. We present an atypical case of Crohn’s disease with necrotizing granulomas that was triggered by Clostridium difficile infection (CDI). CASE REPORT: A 40 years woman presented with chronic diarrhoea and investigations showed CDI. With no sustained...
Low Dose Naltrexone: A Viable Alternative for Long Term Chronic Pain?
Research Type Human Reported as Case Report/Series/Restrospective Study Date March 15, 2019 Authors Victor Rivera; Joseph DeCicco; Samuel Espiritu Institution Naval Medical Center Portsmouth Disease Chronic Pain
Over the past decade there has been significant advancement in understanding the multitude of ways naltrexone interacts with human physiology. The two main theories purported in literature are suppression of cytokine production by glial cells and transient blockade of the mu- opioid receptor. This case report highlights a chronic pain patient that sustained a wean from high dose opioid regimen utilizing low dose naltrexone. Her daily pain score, as calculated using the Defense and Veterans Pain ...